[Featured Stock] Hyundai Bio, Niclosamide Oral COVID-19 Treatment Efficacy Test

[Asia Economy Reporter Park Hyungsoo] Hyundai Bio's stock price is on the rise. The news that efficacy experiments for the niclosamide-based COVID-19 treatment are being actively conducted seems to have had an impact.

As of 2:20 PM on the 2nd, Hyundai Bio is trading at 27,000 KRW, up 15.6% compared to the previous trading day.

Hyundai Bio announced on its website, "From the 2nd to the 9th of this month, animal efficacy experiments for the oral drug 'CP-COV03,' which repurposes niclosamide with improved bioavailability as a COVID-19 treatment, will be conducted at the Institute of Zoonotic Infectious Diseases at Jeonbuk National University."

It added, "The COVID-19 efficacy experiments were originally scheduled to start in early January but were postponed due to sterilization of facilities and equipment inspection at the Institute of Zoonotic Infectious Diseases at Jeonbuk National University in accordance with relevant laws and regulations."